Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection

Chest

Volumn 153, Issue 1, 2018, Pages 266-277

  Kelly, Brendan J ^a   Tebas, Pablo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clostridium difficile infection; fecal microbiota transplantation; microbiome

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FECAL MICROBIOTA TRANSPLANTATION; FOOD AND DRUG ADMINISTRATION; HUMAN; INFECTION RISK; MICROBIAL COMMUNITY; NONHUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT INFECTION; REIMBURSEMENT; REVIEW; TREATMENT INDICATION; ADOLESCENT; ADULT; AGED; CLOSTRIDIUM INFECTION; DONOR SELECTION; MASS COMMUNICATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CLOSTRIDIUM INFECTIONS; DIFFUSION OF INNOVATION; DONOR SELECTION; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 85040181382     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2017.09.002     Document Type: Review

References (136)

1. Bartlett, J.G., Gerding, D.N., Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46:suppl 1 (2008), S12–S18.
2. Cohen, S.H., Gerding, D.N., Johnson, S., et al., and the Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:5 (2010), 431–455.
3. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:4 (2013), 478–498.
4. Dubberke, E.R., Carling, P., Carrico, R., et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 35:6 (2014), 628–645.
5. Eyre, D.W., Cule, M.L., Wilson, D.J., et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 369:13 (2013), 1195–1205.
6. Kumar, N., Miyajima, F., He, M., et al. Genome-based infection tracking reveals dynamics of Clostridium difficile transmission and disease recurrence. Clin Infect Dis 62:6 (2016), 746–752.
7. Seekatz, A.M., Young, V.B., Clostridium difficile and the microbiota. J Clin Invest 124:10 (2014), 4182–4189.
8. Schubert, A.M., Rogers, M.A.M., Ring, C., et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio, 5(3), 2014 e01021-14.
9. Koenigsknecht, M.J., Theriot, C.M., Bergin, I.L., Schumacher, C.A., Schloss, P.D., Young, V.B., Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect Immun 83:3 (2015), 934–941.
10. Schubert, A.M., Sinani, H., Schloss, P.D., Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against. Clostridium difficile. MBio, 6(4), 2015 e00974-15.
11. Buffie, C.G., Bucci, V., Stein, R.R., et al. Precision microbiome reconstitution restores bile acid mediated resistance to. Clostridium difficile. Nature 517:7533 (2015), 205–208.
12. Lewis, B.B., Carter, R.A., Pamer, E.G., Bile acid sensitivity and in vivo virulence of clinical Clostridium difficile isolates. Anaerobe 41 (2016), 32–36.
13. Manges, A.R., Labbe, A., Loo, V.G., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J Infect Dis 202:12 (2010), 1877–1884.
14. Vincent, C., Stephens, D.A., Loo, V.G., et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome, 1(1), 2013, 18.
15. Shreiner, A.B., Kao, J.Y., Young, V.B., The gut microbiome in health and in disease. Curr Opin Gastroenterol 31:1 (2015), 69–75.
16. Lee, Y.J., Arguello, E.P., Jenq, R.R., et al. Protective factors in the intestinal microbiome against Clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation. J Infect Dis 215:7 (2017), 1117–1123.
17. Loo, V.G., Bourgault, A.M., Poirier, L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 365:18 (2011), 1693–1703.
18. Kong, L.Y., Dendukuri, N., Schiller, I., et al. Predictors of asymptomatic Clostridium difficile colonization on hospital admission. Am J Infect Control 43:3 (2015), 248–253.
19. Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N Engl J Med 372:16 (2015), 1539–1548.
20. Arriola, V., Tischendorf, J., Musuuza, J., Barker, A., Rozelle, J.W., Safdar, N., Assessing the risk of hospital-acquired Clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol 37:12 (2016), 1408–1417.
21. Aas, J., Gessert, C.E., Bakken, J.S., Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36:5 (2003), 580–585.
22. Bakken, J.S., Borody, T., Brandt, L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 9:12 (2011), 1044–1049.
23. Brandt, L.J., FMT: first step in a long journey. Am J Gastroenterol 108:8 (2013), 1367–1368.
24. Cammarota, G., Ianiro, G., Gasbarrini, A., and the Fecal Microbiota Transplantation Workgroup. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 48:8 (2014), 693–702.
25. Brandt, L.J., Fecal microbiota transplant: respice, adspice, prospice. J Clin Gastroenterol 49:suppl 1 (2015), S65–S68.
26. Kelly, C.R., Kahn, S., Kashyap, P., et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 149:1 (2015), 223–237.
27. van Nood, E., Vrieze, A., Nieuwdorp, M., et al. Duodenal infusion of donor feces for recurrent. Clostridium difficile. N Engl J Med 368:5 (2013), 407–415.
28. Song, Y., Garg, S., Girotra, M., et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One, 8(11), 2013, e81330.
29. Hamilton, M.J., Weingarden, A.R., Unno, T., Khoruts, A., Sadowsky, M.J., High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 4:2 (2013), 125–135.
30. Seekatz, A.M., Aas, J., Gessert, C.E., et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio, 5(3), 2014 e00893-14.
31. Dutta, S.K., Girotra, M., Garg, S., et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 12:9 (2014), 1572–1576.
32. Weingarden, A., González, A., Vázquez-Baeza, Y., et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome, 3, 2015, 10.
33. Khanna, S., Montassier, E., Schmidt, B., et al. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther 44:7 (2016), 715–727.
34. Jalanka, J., Mattila, E., Jouhten, H., et al. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection. BMC Med, 14(1), 2016, 155.
35. Staley, C., Kelly, C.R., Brandt, L.J., Khoruts, A., Sadowsky, M.J., Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. MBio, 7(6), 2016 e01965-16.
36. Li, S.S., Zhu, A., Benes, V., et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science 352:6285 (2016), 586–589.
37. Bojanova, D.P., Bordenstein, S.R., Fecal transplants: what is being transferred?. PLoS Biol, 14(7), 2016, e1002503.
38. Lessa, F.C., Mu, Y., Bamberg, W.M., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372:9 (2015), 825–834.
39. Gerding, D.N., Lessa, F.C., The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am 29:1 (2015), 37–50.
40. Petrof, E.O., Gloor, G.B., Vanner, S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: “RePOOPulating” the gut. Microbiome, 1(1), 2013, 3.
41. Youngster, I., Sauk, J., Pindar, C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58:11 (2014), 1515–1522.
42. Youngster, I., Russell, G.H., Pindar, C., Ziv-Baran, T., Sauk, J., Hohmann, E.L., Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:17 (2014), 1772–1778.
43. Cammarota, G., Masucci, L., Ianiro, G., et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41:9 (2015), 835–843.
44. Lee, C.H., Steiner, T., Petrof, E.O., et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315:2 (2016), 142–149.
45. Kelly, C.R., Khoruts, A., Staley, C., et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 165:9 (2016), 609–616.
46. Rao, K., Young, V.B., Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 29:1 (2015), 109–122.
47. Hamilton, M.J., Weingarden, A.R., Sadowsky, M.J., Khoruts, A., Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107:5 (2012), 761–767.
48. Kazerouni, A., Burgess, J., Burns, L.J., Wein, L.M., Optimal screening and donor management in a public stool bank. Microbiome, 3(1), 2015, 75.
49. Khoruts, A., Sadowsky, M.J., Hamilton, M.J., Development of fecal microbiota transplantation suitable for mainstream medicine. Clin Gastroenterol Hepatol 13:2 (2015), 246–250.
50. Costello, S.P., Tucker, E.C., La Brooy, J., Schoeman, M.N., Andrews, J.M., Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 62:7 (2016), 908–914.
51. Moore, T., Rodriguez, A., Bakken, J.S., Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin Infect Dis 58:4 (2014), 541–545.
52. Kelly, C.R., Kunde, S.S., Khoruts, A., Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol 12:2 (2014), 283–288.
53. Polage, C.R., Gyorke, C.E., Kennedy, M.A., et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 175:11 (2015), 1792–1801.
54. Polage, C.R., Turkiewicz, J.V., Cohen, S.H., The never-ending struggle with laboratory testing for Clostridium difficile infection. J Comp Eff Res 5:2 (2016), 113–116.
55. Gould, C.V., Edwards, J.R., Cohen, J., et al. and the Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis 57:9 (2013), 1304–1307.
56. Crobach, M.J.T., Planche, T., Eckert, C., et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 22:suppl 4 (2016), S63–S81.
57. Owens, R.C. Jr., Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:suppl 1 (2008), S19–S31.
58. Khanna, S., Pardi, D.S., Aronson, S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107:1 (2012), 89–95.
59. Freedberg, D.E., Salmasian, H., Friedman, C., Abrams, J.A., Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 108:11 (2013), 1794–1801.
60. Chitnis, A.S., Holzbauer, S.M., Belflower, R.M., et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 173:14 (2013), 1359–1367.
61. Lessa, F.C., Mu, Y., Winston, L.G., et al. Determinants of Clostridium difficile infection incidence across diverse United States geographic locations. Open Forum Infect Dis, 1(2), 2014, ofu048.
62. Jackson, M.A., Goodrich, J.K., Maxan, M.E., et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65:5 (2016), 749–756.
63. Khanna, S., Pardi, D.S., Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. Expert Rev Gastroenterol Hepatol 10:10 (2016), 1145–1152.
64. Tariq, R., Singh, S., Gupta, A., Pardi, D.S., Khanna, S., Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med 177:6 (2017), 784–791.
65. Kwon, J.H., Reske, K.A., Hink, T., Burnham, C.A., Dubberke, E.R., Evaluation of correlation between pretest probability for Clostridium difficile infection and Clostridium difficile enzyme immunoassay results. J Clin Microbiol 55:2 (2017), 596–605.
66. Bartlett, J.G., Antibiotic-associated diarrhea. N Engl J Med 346:5 (2002), 334–339.
67. Hohmann, E.L., Ananthakrishnan, A.N., Deshpande, V., Case Records of the Massachusetts General Hospital: case 25-2014—a 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med 371:7 (2014), 668–675.
68. Jackson, M., Olefson, S., Machan, J.T., Kelly, C.R., A high rate of alternative diagnoses in patients referred for presumed Clostridium difficile infection. J Clin Gastroenterol 50:9 (2016), 742–746.
69. Larson, A.M., Fung, A.M., Fang, F.C., Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol 48:1 (2010), 124–130.
70. Tenover, F.C., Novak-Weekley, S., Woods, C.W., et al. Impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J Clin Microbiol 48:10 (2010), 3719–3724.
71. McFarland, L.V., Elmer, G.W., Surawicz, C.M., Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:7 (2002), 1769–1775.
72. Tang-Feldman, Y., Mayo, S., Silva, J. Jr., Cohen, S.H., Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent Clostridium difficile-associated diarrhea. J Clin Microbiol 41:7 (2003), 3413–3414.
73. Seekatz, A.M., Rao, K., Santhosh, K., Young, V.B., Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection. Genome Med, 8(1), 2016, 47.
74. Debast, S.B., Bauer, M.P., Kuijper, E.J., and the European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:suppl 2 (2014), 1–26.
75. Weingarden, A.R., Hamilton, M.J., Sadowsky, M.J., Khoruts, A., Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 47:8 (2013), 735–737.
76. Agrawal, M., Aroniadis, O.C., Brandt, L.J., et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol 50:5 (2016), 403–407.
77. Aroniadis, O.C., Brandt, L.J., Greenberg, A., et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 50:5 (2016), 398–402.
78. Fischer, M., Sipe, B.W., Rogers, N.A., et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther 42:4 (2015), 470–476.
79. Pecere, S., Sabatelli, M., Fantoni, M., Ianiro, G., Gasbarrini, A., Cammarota, G., Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection. [letter] Aliment Pharmacol Ther, 42(8), 2015, 1030.
80. Dial, S., Clostridium difficile colitis: a marker for ischemic colitis?. [letter] CMAJ, 171(11), 2004, 1326.
81. Dallal, R.M., Harbrecht, B.G., Boujoukas, A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 235:3 (2002), 363–372.
82. Mulki, R., Baumann, A.J., Alnabelsi, T., et al. Body mass index greater than 35 is associated with severe Clostridium difficile infection. Aliment Pharmacol Ther 45:1 (2017), 75–81.
83. Dignan, C.R., Greenson, J.K., Can ischemic colitis be differentiated from C difficile colitis in biopsy specimens?. Am J Surg Pathol 21:6 (1997), 706–710.
84. Tang, D.M., Urrunaga, N.H., De Groot, H., von Rosenvinge, E.C., Xie, G., Ghazi, L.J., Pseudomembranous colitis: not always caused by Clostridium difficile. Case Rep Med, 2014, 2014, 812704.
85. Solari, P.R., Fairchild, P.G., Noa, L.J., Wallace, M.R., Tempered enthusiasm for fecal transplant. [letter] Clin Infect Dis, 59(2), 2014, 319.
86. Kelly, C.R., Ihunnah, C., Fischer, M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 109:7 (2014), 1065–1071.
87. US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Implementation of acceptable full-length and abbreviated donor history questionnaires and accompanying materials for use in screening donors of blood and blood components: guidance for industry. https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm273685.pdf. Accessed September 22, 2017.
88. Rohlke, F., Stollman, N., Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 5:6 (2012), 403–420.
89. Alang, N., Kelly, C.R., Weight gain after fecal microbiota transplantation. Open Forum Infect Dis, 2(1), 2015, ofv004.
90. Weil, A.A., Hohmann, E.L., Fecal microbiota transplant: benefits and risks. Open Forum Infect Dis, 2(1), 2015, ofv005.
91. Mattila, E., Uusitalo-Seppälä R., Wuorela, M., et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 142:3 (2012), 490–496.
92. Government of Canada. Guidance document: fecal microbiota therapy used in the treatment of Clostridium difficile infection not responsive to standard therapies. https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/biologics-radiopharmaceuticals-genetic-therapies/guidance-document-regulation-fecal-microbiota-therapy.html. Accessed September 22, 2017.
93. OpenBiome. Quality & Safety Program. https://static1.squarespace.com/static/50e0c29ae4b0a05702af7e6a/t/59304bdf3e00be24622791fb/1496337376745/The+OpenBiome+Quality+%26+Safety+Program.pdf. Accessed September 1, 2017.
94. Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S. Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection [published online ahead of print December 14, 2016]. J Clin Gastroenterol. https://doi.org/10.1097/MCG.0000000000000768.
95. Sokol, H., Galperine, T., Kapel, N., et al., and the French Group of Faecal microbiota Transplantation. Faecal microbiota transplantation in recurrent Clostridium difficile infection: recommendations from the French Group of Faecal microbiota Transplantation. Dig Liver Dis 48:3 (2016), 242–247.
96. Craven LJ, Gloor G, Reid G, Silverman M, Burton JP. What are the optimal long-term storage conditions for donor samples used in fecal microbiota transplantation? Abstract presented at: ASM Microbe 2017 meeting; June 3, 2017; New Orleans, LA.
97. Paterson AS, Kissoon M, Surangiwala S, Willey BM, Hota S, Poutanen SM. Determination of optimal duration and conditions for long-term storage of fecal filtrate samples. Abstract presented at: ASM Microbe 2017 meeting; June 4, 2017; New Orleans, LA.
98. OpenBiome. FMT capsule G3 clinical primer. https://www.openbiome.org/s/G3-Capsules-Clinical-Primer. Accessed September 22, 2017.
99. Kassam, Z., Lee, C.H., Yuan, Y., Hunt, R.H., Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108:4 (2013), 500–508.
100. Simon, G.L., Gorbach, S.L., Intestinal flora in health and disease. Gastroenterology 86:1 (1984), 174–193.
101. Franks, A.H., Harmsen, H.J.M., Raangs, G.C., Jansen, G.J., Schut, F., Welling, G.W., Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 64:9 (1998), 3336–3345.
102. Gough, E., Shaikh, H., Manges, A.R., Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53:10 (2011), 994–1002.
103. Postigo, R., Kim, J.H., Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 40:6 (2012), 643–648.
104. Sofi, A.A., Silverman, A.L., Khuder, S., Garborg, K., Westerink, J.M.A., Nawras, A., Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection: pooled data analysis and a systematic review. Scand J Gastroenterol 48:3 (2013), 266–273.
105. Stollman, N., Smith, M., Giovanelli, A., et al. Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. Am J Gastroenterol 110:4 (2015), 600–601.
106. Jalanka, J., Salonen, A., Salojärvi, J., et al. Effects of bowel cleansing on the intestinal microbiota. Gut 64:10 (2015), 1562–1568.
107. Youngster, I., Mahabamunuge, J., Systrom, H.K., et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med, 14(1), 2016, 134.
108. Khoruts, A., Rank, K.M., Newman, K.M., et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 14:10 (2016), 1433–1438.
109. Fischer, M., Kao, D., Mehta, S.R., et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 111:7 (2016), 1024–1031.
110. Fischer, M., Kao, D., Kelly, C., et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22:10 (2016), 2402–2409.
111. Hota, S.S., Sales, V., Tomlinson, G., et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis 64:3 (2017), 265–271.
112. Bokek-Cohen, Y., Ravitsky, V., Cultural and personal considerations in informed consent for fecal microbiota transplantation. [abstract] Am J Bioeth 17:5 (2017), 55–57.
113. Ma, Y., Liu, J., Rhodes, C., Nie, Y., Zhang, F., Ethical issues in fecal microbiota transplantation in practice. Am J Bioeth 17:5 (2017), 34–45.
114. Bunnik, E.M., Aarts, N., Chen, L.A., Physicians must discuss potential long-term risks of fecal microbiota transplantation to ensure informed consent. Am J Bioeth 17:5 (2017), 61–63.
115. Bakken, J.S., Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect Dis 59:6 (2014), 858–861.
116. Lowy, I., Molrine, D.C., Leav, B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:3 (2010), 197–205.
117. Gupta, S.B., Mehta, V., Dubberke, E.R., et al. Antibodies to toxin B are protective against Clostridium difficile infection recurrence. Clin Infect Dis 63:6 (2016), 730–734.
118. Cornely, O.A., Vehreschild, M.J.G.T., Where to place the new treatments for Clostridium difficile infection?. [editorial commentary] Clin Infect Dis 63:6 (2016), 735–736.
119. Neal, M.D., Alverdy, J.C., Hall, D.E., Simmons, R.L., Zuckerbraun, B.S., Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254:3 (2011), 423–427.
120. Moayyedi, P., Surette, M.G., Kim, P.T., et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 149(1), 2015 102.e6-109.e6.
121. Jacob, V., Crawford, C., Cohen-Mekelburg, S., et al. Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis. Inflamm Bowel Dis 23:6 (2017), 903–911.
122. Paramsothy, S., Kamm, M.A., Kaakoush, N.O., et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389:10075 (2017), 1218–1228.
123. Grinspan, A.M., Kelly, C.R., Fecal microbiota transplantation for ulcerative colitis: not just yet. Gastroenterology 149:1 (2015), 15–18.
124. Tariq, R., Smyrk, T., Pardi, D.S., Tremaine, W.J., Khanna, S., New-onset microscopic colitis in an ulcerative colitis patient after fecal microbiota transplantation. Am J Gastroenterol 111:5 (2016), 751–752.
125. Singh, R., van Nood, E., Nieuwdorp, M., et al. Donor feces infusion for eradication of Extended Spectrum beta-Lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect 20:11 (2014), O977–O978.
126. Crum-Cianflone, N.F., Sullivan, E., Ballon-Landa, G., Fecal microbiota transplantation and successful resolution of multidrug-resistant-organism colonization. J Clin Microbiol 53:6 (2015), 1986–1989.
127. Borody, T., Fischer, M., Mitchell, S., Campbell, J., Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead. Expert Rev Gastroenterol Hepatol 9:11 (2015), 1379–1391.
128. Millan, B., Park, H., Hotte, N., et al. Fecal microbial transplants reduce antibiotic-resistant genes in patients with recurrent Clostridium difficile infection. Clin Infect Dis 62:12 (2016), 1479–1486.
129. Biliński, J., Grzesiowski, P., Muszyński, J., et al. Fecal microbiota transplantation inhibits multidrug-resistant gut pathogens: preliminary report performed in an immunocompromised host. Arch Immunol Ther Exp (Warsz) 64:3 (2016), 255–258.
130. Araos, R., Tai, A.K., Snyder, G.M., Blaser, M.J., D'Agata, E.M.C., Predominance of Lactobacillus spp. among patients who do not acquire multidrug-resistant organisms. Clin Infect Dis 63:7 (2016), 937–943.
131. Bilinski, J., Grzesiowski, P., Sorensen, N., et al. Fecal microbiota transplantation in patients with blood disorders inhibits gut colonization with antibiotic-resistant bacteria: results of a prospective, single-center study. Clin Infect Dis 65:3 (2017), 364–370.
132. Food and Drug Administration Center for Biologics Evaluation and Research. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies: draft guidance for industry, March 2016. https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm488223.pdf. Accessed September 1, 2017.
133. Konijeti, G.G., Sauk, J., Shrime, M.G., Gupta, M., Ananthakrishnan, A.N., Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 58:11 (2014), 1507–1514.
134. Varier, R.U., Biltaji, E., Smith, K.J., et al. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol 36:4 (2015), 438–444.
135. Baro, E., Galperine, T., Denies, F., et al. Cost-effectiveness analysis of five competing strategies for the management of multiple recurrent community-onset Clostridium difficile infection in France. PLoS One, 12(1), 2017, e0170258.
136. OpenBiome. The OpenBiome billing guide: a guide to physician and hospital billing for using OpenBiome fecal microbiota preparations. https://static1.squarespace.com/static/50e0c29ae4b0a05702af7e6a/t/578e3711579fb3d7cbe44eaa/1468938001601/Billing+Guide.pdf. Accessed September 22, 2017.